State Board of Administration of Florida Retirement System increased its stake in Heron Therapeutics Inc. (NASDAQ:HRTX) by 8.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,739 shares of the biotechnology company’s stock after buying an additional 1,283 shares during the period. State Board of Administration of Florida Retirement System’s holdings in Heron Therapeutics were worth $302,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of the company. JPMorgan Chase & Co. raised its stake in shares of Heron Therapeutics by 6.0% in the first quarter. JPMorgan Chase & Co. now owns 348,685 shares of the biotechnology company’s stock valued at $6,622,000 after buying an additional 19,737 shares during the last quarter. VHCP Management II LLC acquired a new stake in shares of Heron Therapeutics during the first quarter valued at approximately $7,708,000. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Heron Therapeutics during the first quarter valued at approximately $734,000. Panagora Asset Management Inc. raised its stake in shares of Heron Therapeutics by 90.3% in the first quarter. Panagora Asset Management Inc. now owns 245,392 shares of the biotechnology company’s stock valued at $4,660,000 after buying an additional 116,461 shares during the last quarter. Finally, Cormorant Asset Management LLC raised its stake in shares of Heron Therapeutics by 3.8% in the first quarter. Cormorant Asset Management LLC now owns 1,750,000 shares of the biotechnology company’s stock valued at $33,233,000 after buying an additional 64,281 shares during the last quarter.
Shares of Heron Therapeutics Inc. (NASDAQ:HRTX) traded down 0.71% during trading on Friday, reaching $15.31. The company had a trading volume of 118,200 shares. The firm’s 50 day moving average price is $18.11 and its 200 day moving average price is $18.86. Heron Therapeutics Inc. has a 12 month low of $15.13 and a 12 month high of $31.32.
Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Monday, August 8th. The biotechnology company reported ($1.17) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.96) by $0.21. Equities research analysts forecast that Heron Therapeutics Inc. will post ($4.39) EPS for the current fiscal year.
HRTX has been the topic of several research analyst reports. Cantor Fitzgerald reissued a “buy” rating and issued a $41.00 price objective on shares of Heron Therapeutics in a report on Friday, June 24th. Leerink Swann reissued a “buy” rating on shares of Heron Therapeutics in a report on Monday, June 27th. Cowen and Company reissued a “buy” rating on shares of Heron Therapeutics in a report on Saturday, July 9th. Jefferies Group reissued a “buy” rating and issued a $46.00 price objective on shares of Heron Therapeutics in a report on Wednesday, July 27th. Finally, Zacks Investment Research lowered Heron Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 3rd. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Heron Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $42.29.
In other Heron Therapeutics news, insider Robert Rosen sold 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 10th. The stock was sold at an average price of $23.30, for a total transaction of $2,330,000.00. Following the completion of the sale, the insider now directly owns 102,640 shares of the company’s stock, valued at approximately $2,391,512. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 20.31% of the company’s stock.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics Inc. (NASDAQ:HRTX).
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.